SAN DIEGO, October 27, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective ...

The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. This story was originally published on MedTech Dive. To receive daily news and insights, ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

The company’s strong financial health score of "GREAT" on InvestingPro supports this outlook, with robust cash flows and moderate debt levels. TD Cowen expects DexCom’s upcoming third-quarter results ...

Dexcom ((DXCM)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

DexCom was hit with a consumer class action on Oct. 22 in California Southern District Court over allegations it made unauthorized design changes to its G6 and G7 continuous glucose monitors without ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.

DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a ...

13 analysts have expressed a variety of opinions on DexCom (NASDAQ:DXCM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

SAN DIEGO - Dexcom, Inc. (NASDAQ:DXCM), a glucose biosensing technology company with a market capitalization of $27.69 billion and an "GREAT" financial health rating according to InvestingPro, ...